###begin article-title 0
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Somatic inactivation of the TP53 gene in breast tumors is a marker for poor outcome, and breast cancer outcome might also be affected by germ-line variation in the TP53 gene or its regulators. We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749). Overall and breast cancer-specific survival analyses were performed using Kaplan-Meier analysis and multivariate Cox's proportional hazards regression models.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 611 613 611 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 642 644 642 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 843 848 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 928 930 928 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 975 977 975 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 1035 1040 1035 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 425 432 <span type="species:ncbi:9606">patient</span>
Survival of patients did not differ by carriership of either germ-line variant, R72P (215G>C) or SNP309 (-410G>T) alone. Immunohistochemical p53 staining of the tumor was available for two cohorts (n = 1,109 patients). Survival was worse in patients with p53-positive tumors (n = 301) compared to patients with p53-negative tumors (n = 808); breast cancer-specific survival: HR 1.6 (95% CI 1.2 to 2.1), P = 0.001. Within the patient group with p53-negative tumors, TP53 rare homozygous (CC) carriers had a worse survival than G-allele (GG/GC) carriers; actuarial breast cancer-specific survival 71% versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03. We also found a differential effect of combinations of the two germ-line variants on overall survival; homozygous carriers of the G-allele in MDM2 had worse survival only within the group of TP53 C-allele carriers; actuarial overall survival (GG versus TT/TG) 64% versus 75%, P = 0.001; HR (GG versus TT) 1.5 (1.1 to 2.0), P = 0.01. We found no evidence for a differential effect of MDM2 SNP309 by p53 protein expression on survival.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
The TP53 R72P variant may be an independent predictor for survival of patients with p53-negative tumors. The combined effect of TP53 R72P and MDM2 SNP309 on survival is in line with our a priori biologically-supported hypothesis, that is, the role of enhanced DNA repair function of the TP53 Pro-variant, combined with increased expression of the Mdm2 protein, and thus overall attenuation of the p53 pathway in the tumor cells.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 942 943 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 961 962 961 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Breast cancer outcome may be affected by germ-line variants in genes that play a role in DNA damage control and repair such as TP53 (R72P) and MDM2 (SNP309) [1,2]. The Mdm2 protein is a negative regulator of the tumor suppressor protein p53 [3]. The R72P (215G>C) polymorphism of the TP53 gene is located in a proline-rich region of p53 suggested to be required for the growth suppression activity of p53 [4] and for its ability to induce apoptosis [5]. The two variant protein forms, R72 (arginine) and 72P (proline), have been shown to differ in their biological functions: the R72 variant is a stronger and faster inducer of apoptosis than the 72P variant [6,7]. The 72P variant also binds more efficiently to iASPP, an inhibitor of pro-apoptotic function of p53, which may be another reason for the inferiority in apoptosis induction of this variant [8]. The 72P variant has been found to be more efficient in inducing cell-cycle arrest [7] and DNA repair [9] than the R72 variant which may protect tumor from chemotherapy-induced apoptosis.
###end p 10
###begin p 11
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 561 562 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
Previous studies have shown that the R72P polymorphism is not associated with increased breast cancer risk [1,10,11]. However, an association of R72P with breast cancer survival has been suggested, though with inconsistent results and possibly only in patients with p53-negative tumors [10-16]. It has also been suggested that patients with the Pro/Pro genotype are less sensitive to anthracycline-based treatment than those with the Arg/Pro or Arg/Arg genotype [14,16], in line with the Pro-allele being more efficient in cell-cycle arrest [7] and DNA repair [9] induction.
###end p 11
###begin p 12
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
A common single nucleotide polymorphism in the MDM2 promoter region, a T to G change at nucleotide 309 in the first intron (-410G>T; named SNP309), has been shown to create an improved Sp1 binding site, leading to increased expression of the Mdm2 protein and thus attenuation of the p53 pathway and accelerated tumor formation in individuals carrying a germ-line p53 mutation [17-19]. A number of small studies revealed an inconsistent association between SNP309 and breast cancer risk (see overview in [1], and [20,21]). However, we have shown in a large pooled analyses of the Breast Cancer Association Consortium series that there is no general association of SNP309 with breast cancer, nor if stratified by estrogen receptor (ER) [1].
###end p 12
###begin p 13
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 542 550 542 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1/2 </italic>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 652 657 652 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
In two small studies no association between breast cancer survival and MDM2 SNP309 genotype alone was found [13,22]. However, the results of one of those studies suggested a differential effect of MDM2 SNP309 genotype by tumor p53 status (mutant p53 or aberrant protein expression) on breast cancer survival [22]. Though MDM2 SNP309 has been implicated to affect survival in other tumors (for example, [23]), as far as we know there are no other publications on breast cancer outcome and this polymorphism, except for a recent publication in BRCA1/2 carriers of Ashkenazi origin [24]. Our aim was to investigate the combined effects of MDM2 SNP309 and TP53 R72P polymorphisms and p53 protein expression on breast cancer survival.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Clinico-pathologic data and genotyping
###end title 15
###begin p 16
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 810 815 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 967 968 967 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1152 1154 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 144 152 <span type="species:ncbi:9606">Patients</span>
###xml 255 262 <span type="species:ncbi:9606">Patient</span>
###xml 536 541 <span type="species:ncbi:10090">mouse</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
Breast cancer cases from four European studies within the Breast Cancer Association Consortium were included in this analysis (Table 1) [1,25]. Patients that were genotyped for MDM2 SNP309 and TP53 R72P from studies with follow-up data were included [1]. Patient selection criteria, participation rates and information on the collection of follow-up and clinical data are shown in Table 1. P53 protein expression data were available for two of the four studies (Table 1). Immunohistochemical staining of TMA slides was performed with a mouse monoclonal anti-human p53-antibody (DO-7, DAKO) (Table 1). Missing p53 data could be attributed to missing tumor blocks, loss of cores in the slicing or staining process or cores not containing enough tumor material. P53 protein expression scoring and MDM2 SNP309 and TP53 R72P genotyping were performed blinded to the survival status of the patients. Genotyping assays were performed by each group separately [1] (see Table 1 for assay description). Primer (and probe) sequences are available from the authors upon request. Methods and results in this paper are reported following the REMARK recommendations [26]. All studies were approved by the appropriate (Medical) Ethical Research Committees.
###end p 16
###begin p 17
Characteristics of the studies and genotyping assays
###end p 17
###begin p 18
*IHC = immunohistochemistry; TMA = Tissue Micro Array; NA = not applicable (no p53 data available).
###end p 18
###begin title 19
Statistical analyses
###end title 19
###begin p 20
###xml 1488 1489 1488 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1663 1665 1663 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
Univariate analyses of survival were performed by calculating Kaplan-Meier survival curves and comparing subsets of patients using log-rank test. To explore the effects of several variables and their combined effects on survival, multivariate Cox's proportional hazards regression models were used (reported as Hazard Ratio (HR) with 95% confidence interval). Results are reported for one polymorphisms stratified by the other polymorphisms or p53 expression, adjusted for other covariates. Interaction terms were tested by Cox regression models including the main effects (2df each), interaction terms, for example, four interaction terms for both polymorphisms, and other covariates. Covariates included were prognostic factors for breast cancer survival, that is, age, stage, grade and ER and p53 protein expression. In order to run models including all patients, missing value categories were included for each separate variable with missing information. Polymorphisms were included as categorical variables (with the homozygous common allele group as reference), or as a continuous variable in the per-allele analyses. All pooled analyses were adjusted for study, that is, ABCS, HABCS, HEBCS, SEARCH, included as a categorical variable. Breast cancer-specific survival was defined as survival until death from breast cancer, with breast cancer being the underlying cause of death; death due to other causes was censored (these analyses included the ABCS and HEBCS studies, see Table 1). Overall survival was defined as survival until death of any cause. In all analyses, follow-up time was censored at 10 years. All statistical tests used were two-sided and P values < 0.05 were considered statistically significant. All analyses were performed using SPSS 15.0 (SPSS Inc, Chicago, IL, USA).
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 22
###begin p 23
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 649 650 649 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 799 800 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 532 539 <span type="species:ncbi:9606">patient</span>
###xml 615 622 <span type="species:ncbi:9606">patient</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
Breast cancer patients with follow-up and TP53 R72P and MDM2 SNP309 genotypes from three hospital-based and one population-based study within the Breast Cancer Association Consortium were included for analysis (n = 3,749) (Table 1). Frequencies of TP53 R72P and MDM2 SNP309 and clinicopathologic characteristics of the breast cancer patients in the four studies are shown in Table 2. We have described and discussed earlier the small difference in MDM2 SNP309 allele frequencies between European populations [1] while difference in patient characteristics between studies can mostly be attributed to differences in patient selection criteria (Table 1). Mean follow-up was 7.7 years (SD 4). A small number patients (n = 26) were carriers of the homozygous rare variants for both polymorphisms (Table 3).
###end p 23
###begin p 24
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Germ-line variants and clinicopathologic characteristics of breast cancer patients by study
###end p 24
###begin p 25
###xml 2 4 2 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
* P value of comparison of either categories of non-missing data among studies (by chi-square) or comparison of continuous data (by t-test).
###end p 25
###begin p 26
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Frequencies of TP53 R72P and MDM2 SNP309 germ-line variants
###end p 26
###begin title 27
Breast cancer survival by TP53 R72P, MDM2 SNP309 genotype, and p53 tumor status
###end title 27
###begin p 28
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 389 391 389 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
Overall survival of patients did not differ by carriership of either germ-line variant, R72P or SNP309, alone in the pooled analyses (Table 4). Tumor p53 status was available for 1109 patients from the ABCS and HEBCS series (Table 1). In both series, the patients with p53-positive tumors showed poorer overall survival than the patients with p53-negative tumors (pooled HR 1.5 (1.2-1.9), P = 0.002; Table 4).
###end p 28
###begin p 29
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
HR estimates of overall survival* by TP53 R72P, MDM2 SNP309 and p53
###end p 29
###begin p 30
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 264 270 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*Overall survival including all studies unless otherwise specified; ** HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of common alleles: TP53 R72P = GG; MDM2 SNP309 = TT; p53 = negative tumors; daggerPooled analyses have been adjusted for study.
###end p 30
###begin title 31
Differential effect of TP53 R72P on breast cancer survival stratified for p53 tumor status
###end title 31
###begin p 32
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 302 304 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 738 740 738 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 892 894 892 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 908 909 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 7 14 <span type="species:ncbi:9606">patient</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">Patients</span>
In the patient group with p53-negative tumors, the actuarial breast cancer-specific survival for the patients carrying the TP53 CC genotype (Pro/Pro) was worse, though not statistically significantly, at 10 years of follow-up as compared to those carrying TP53 GG/GC (Arg/Arg; Arg/Pro) (71% versus 80% P = 0.07; Figure 1). The interaction terms between p53 expression and TP53 R72P were not significant in a multivariate Cox regression analysis, but considering the difference seen in the actuarial curves we still considered it useful to perform Cox analyses stratified for p53 expression. Patients with the TP53 CC genotype had worse breast-cancer specific survival (HR adjusted for study, age, stage, grade and ER: 1.79 (1.05 to 3.05, P = 0.03) (Table 5). Results for overall survival were in line with those of breast-cancer specific survival, but did not reach statistical significance (P = 0.06, Table 5).
###end p 32
###begin p 33
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 240 242 240 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Cumulative breast cancer-specific survival (Kaplan Meier) of breast cancer patients with p53 negative tumors stratified by TP53 R72P. Survival in the TP53 CC group was worse compared to that in the GC and GG group combined (80% versus 71%, P = 0.07).
###end p 33
###begin p 34
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
HR estimates of overall and breast cancer-specific survival by TP53 R72P, in p53 negative and positive tumors (multivariate models)
###end p 34
###begin p 35
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Pooled analyses for studies with p53 information (ABCS and HEBCS); HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of the homozygous common allele: TP53 R72P = GG, and MDM2 SNP309 = TT; analyses have been adjusted for study, age, stage, grade and ER.
###end p 35
###begin p 36
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 11 18 <span type="species:ncbi:9606">patient</span>
Within the patient group with p53-positive tumors, breast cancer-specific survival stratified by TP53 R72P seemed to show inconsistent results between studies though none were significant, that is, per allele HR (adjusted for age, stage, grade and ER) in the ABCS study was 0.74 (0.45 to 1.22) and in the HEBCS study 1.46 (0.79 to 2.69). The pooled HR (adjusted for study, age, stage, grade and ER) was 0.82 (0.53 to 1.27) for heterozygous and 0.86 (0.34 to 2.18) for homozygous C-allele carriers (Table 5). There was no evidence for a differential effect of MDM2 SNP309 by p53 tumor status on survival (Table 5).
###end p 36
###begin title 37
Combined effects of TP53 R72P and MDM2 SNP309 on breast cancer survival
###end title 37
###begin p 38
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 267 269 267 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 452 457 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 546 548 546 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 655 660 655 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 667 672 667 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 692 694 692 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 745 750 745 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 789 791 789 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 888 893 888 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 918 919 918 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 933 938 933 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 997 1002 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 1030 1035 1030 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1080 1085 1080 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1122 1124 1122 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 1139 1144 1139 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1180 1182 1180 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 1196 1197 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">6</xref>
###xml 1207 1212 1207 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1312 1314 1312 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
MDM2 SNP309 showed a differential actuarial overall survival stratified by TP53 R72P in the pooled analyses (n = 3,749), that is, homozygous carriers of the G-allele in MDM2 had worse survival within the group of TP53 GC carriers (GG: 65% versus GT: 72% and TT: 76%, P = 0.006; Figure 2). The same trend was visible in the TP53 homozygous CC group (n = 26 GG/CC), but this was not statistically significant. Within the TP53 C-allele carriers combined, MDM2 GG carriers had significantly worse survival compared to TT/TG carriers: 64% versus 75%, P = 0.001. In multivariate analyses (adjusting for study, age, stage, grade and ER) the interaction term for TP53 GC and MDM2 GG was significant (P = 0.028), also if additional interaction terms for TP53 R72P and p53 expression were included (P = 0.027). The multivariate models (adjusting for study, age, stage, grade and ER) stratified for TP53 R72P (analogue to Figure 2) showed that MDM2 GG carriers had significantly worse survival compared with MDM2 TT carriers only within the TP53 C-allele carriers; more specifically, within TP53 CG carriers: HR 1.43 (1.05 to 1.96), P = 0.02; within TP53 CC carriers HR 1.39 (0.56 to 3.48), P = 0.48 (Table 6); within TP53 CG and CC carriers combined: HR (adjusted for study, age, stage, grade and ER) 1.46 (1.09 to 1.96), P = 0.01.
###end p 38
###begin p 39
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 206 210 206 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a) </bold>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 233 237 233 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(b) </bold>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 255 257 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 267 271 267 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(c) </bold>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 621 623 621 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Cumulative overall survival of breast cancer patients by MDM2 SNP309 and TP53 R72P genotypes. Each figure shows Kaplan Meier survival curves of MDM2 SNP309 genotypes within one group of TP53 R72P genotype. (a) TP53 GG genotype (ns); (b) TP53 GC genotype (P = 0.006); (c) TP53 CC genotype (ns). The numbers at start of follow-up were: Figure A: TT n = 798, TG n = 939, GG n = 281; B: TT n = 545, TG n = 698, GG n = 200; C: TT n = 110, TG n = 144, GG n = 25. Within the TP53 C-allele carriers (Figure A and B combined), MDM2 GG carriers had significantly worse survival compared to TT/TG carriers combined: 64% versus 75%, P = 0.001.
###end p 39
###begin p 40
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
HR estimates of multivariate analyses for MDM2 SNP309 stratified by TP53 R72P
###end p 40
###begin p 41
Models have also been adjusted for study.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 894 896 894 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1129 1131 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 683 691 <span type="species:ncbi:9606">patients</span>
###xml 741 749 <span type="species:ncbi:9606">patients</span>
###xml 947 955 <span type="species:ncbi:9606">patients</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
In the survival analyses including 3,749 breast cancer patients from Finland, The Netherlands, Germany and United Kingdom, we showed combined effects of two germ-line polymorphisms, TP53 R72P, MDM2 SNP309, and p53 tumor expression (by immunohistochemistry). Firstly, we confirmed our earlier observation in Finnish patients [10] that TP53 R72P homozygous carriership predicts a worse survival in patients with p53-negative tumors, also when adjusted for clinical prognostic variables. Thus, in the absence of inactivating p53 mutations in the tumor, the 72P variant form of p53 protein may have a compromising effect on the p53 apoptotic function, leading to reduced survival of the patients. Similarly, a study of 414 Chinese breast cancer patients reported that the 72P homozygous (CC) genotype was associated with both poorer five-year overall survival (five to eight percentile difference, P = 0.04) and poorer disease-free survival among the patients with a wild-type p53 in their tumors (n = 346) [16]. In line with other studies published we did not observe an effect of carriership of R72P alone on survival of patients [12-16].
###end p 43
###begin p 44
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
No significant difference in survival by TP53 R72P carriership was observed among the patients with p53-positive tumors, who showed a worse survival overall compared to p53-negative tumors. In the pooled analysis, CC homozygote patients with p53-positive tumors even tended to have a better survival. In the study by Xu et al. in Chinese breast cancer patients [16], the CC homozygote patients also had non-significant better survival than the GG homozygotes and heterozygotes within the group of patients with p53-mutated tumors.
###end p 44
###begin p 45
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
The finding of CC homozygote (72P) carriers having poorer survival is consistent with the R72 variant of wild-type p53 being a more potent inducer of apoptosis than the wild-type 72P variant. It has been suggested that R72 homozygotes may respond more favorably to radiation or chemotherapy [27]. Response rate after chemo-radiotherapy of advanced squamous cell carcinomas of head and neck and survival was higher in patients with the R72 allele compared to those with the 72P allele [28]. These favorable effects of the R72 allele may, however, be reversed by a somatic p53 mutation on this allele, as has been reported in squamous cell carcinomas of head and neck [29,30]. In line with this, retention of the R72 allele with loss of the 72P allele in the tumor tissue has been associated with reduced survival in heterozygous breast cancer patients [31].
###end p 45
###begin p 46
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Carriership of MDM2 SNP309 alone did not affect survival of patients in our study and two other, smaller studies [13,22]. However, we found an 11 percentile survival difference for homozygous MDM2 G-allele carriers within the group of TP53 C-allele (72P) carriers. Biologically this seems plausible considering the reduced apoptotic function of the TP53 Pro-variant [6,7] and the attenuation of the p53 pathway by mdm2, the production of which is increased by the SNP309 G-variant [17]. In addition, the interaction of both polymorphisms remained statistically significant in multivariate models adjusting for clinical prognostic factors.
###end p 46
###begin p 47
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
We did not observe evidence for a combined effect of SNP309 and p53 tumor expression (as shown here by results of SNP309 stratified by p53 status in Table 5, but obviously p53 did also not have a differential effect on survival stratified by SNP309). This is in contrast to a previous, smaller study (n = 248) in the American population, which suggested that tumor p53 status was associated with breast cancer survival only among patients homozygous for the MDM2 SNP309 T-allele and not among carriers of the variant G-allele [22]. Though our study is one of the largest published studies on combined effects of the germline genetic variation and tumor somatic events, the numbers are still small for looking at such modifying effects on survival.
###end p 47
###begin p 48
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
Many studies have confirmed that mutated p53 is a prognostic factor in breast cancer. The risk of dying of breast cancer for patients with a p53 mutation in their tumor has been estimated to be two to five-fold compared to patients with wild-type p53 tumors [32,33]. Positive immunostaining for p53 is in general considered to indicate somatic p53 mutation and an impaired p53 pathway, though the correlation with TP53 mutations is incomplete [34,35]. The accumulation of p53 in the tumors detected by immunohistochemistry was a prognostic marker of poorer survival in both our series with p53 immunohistochemistry data available (the HEBCS and ABCS series). This effect was somewhat stronger in the HEBCS series, which may be explained by the more stringent cut-off used (20% positive tumor cells compared to 10% in the ABCS series).
###end p 48
###begin title 49
Conclusions
###end title 49
###begin p 50
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 1281 1286 1281 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1295 1300 1295 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 1535 1540 1535 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1549 1554 1549 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 967 974 <span type="species:ncbi:9606">patient</span>
We have shown here that TP53 R72P may have additional prognostic value especially among patients with p53-negative tumors. However, the effect of p53 on outcome may be influenced by adjuvant systemic therapy (for example, [31,36], reviewed in Bertheau [37]) and larger studies will be needed to address this question. Our study is one of the few that have shown an interaction of germ-line variants, that is, TP53 R72P and MDM2 SNP309, in breast cancer survival. The results, showing a statistically significant interaction of the p53 Pro-variant and the GG genotype of MDM2 SNP309, are in line with our a priori biologically-supported hypothesis, which is, the role of enhanced DNA repair function of the Pro-variant, combined with increased expression of the Mdm2 protein, and thus overall attenuation of the p53 pathway in the tumor cells. These results suggest that even subtle differences in p53 apoptotic function caused by synergistic polymorphisms may affect patient's survival, possibly by modifying treatment response. Altogether, our findings are in line with biological evidence in literature, and in the future, may have also clinical significance for models of breast cancer prognosis or treatment. However, because this is the first report on the combined effect of TP53 R72P and MDM2 SNP309 on breast cancer survival and we cannot exclude a chance finding, other studies to confirm this will be necessary. Larger studies will be needed also to investigate the effect of specific treatment modalities on the survival by TP53 R72P and MDM2 SNP309.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
ABCS: Amsterdam Breast Cancer Study; ER: estrogen receptor; HABCS: Hannover Breast Cancer Study; HEBCS: Helsinki Breast Cancer Study; HR: hazard ratio; SD: standard deviation; SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity; TMA: tissue micro array.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
MKS, TD and HN took final responsibility for the decision to submit the paper for publication; all other authors read and approved the manuscript. MKS, JT, FEVL, LJVTV, PDPP, DFE, TD, CB, HN were responsible for the study design. MKS, JT, AB, MS, MH, TD, SAR, RF were responsible for data acquisition and collection. MKS and JT did the data analyses. Data interpretation was carried out by MKS, JT, AB, RF, CB, and HN. MKS, AB, TD, CB, and HN wrote the paper. All authors read and approved the manuscript.
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
###xml 564 570 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 117 124 <span type="species:ncbi:9606">patient</span>
We wish to thank Dr Hannaleena Eerola and Dr Kirsimari Aaltonen and Nina Puolakka RN for their help with the Finnish patient data. The Finnish Cancer registry is gratefully acknowledged for the cancer data. The Helsinki study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), Finnish Cancer Society, the Sigrid Juselius Foundation, and the Ida Montin Foundation. We highly appreciate the contributions of our Dutch colleagues at the NKI-AVL, among others Renate Udo, Linde Braaf and Hans Petersedagger; and at LUMC: Rob Tollenaar, Vincent Smit and Cees Cornelisse; the Dutch study was financed by the Dutch Cancer Society (NKI 2001-2423; 2007-3839) and the Cancer Genomics Center (Dutch Genomics Initiative). We are grateful to our German colleagues Michael Bremer, Andreas Meyer, Johann H. Karstens and Peter Hillemanns for their support of the study at Hannover Medical School. The SEARCH study is funded by Cancer Research UK, and DFE is a Principal Research Fellow and PDP is a Senior Clinical Research Fellow of CRUK.
###end p 58
###begin article-title 59
Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium
###end article-title 59
###begin article-title 60
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer
###end article-title 60
###begin article-title 61
MDM2 is a central node in the p53 pathway: 12 years and counting
###end article-title 61
###begin article-title 62
Identification of a novel p53 functional domain that is necessary for efficient growth suppression
###end article-title 62
###begin article-title 63
The polyproline region of p53 is required to activate apoptosis but not growth arrest
###end article-title 63
###begin article-title 64
Two polymorphic variants of wild-type p53 differ biochemically and biologically
###end article-title 64
###begin article-title 65
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
###end article-title 65
###begin article-title 66
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53
###end article-title 66
###begin article-title 67
Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development
###end article-title 67
###begin article-title 68
###xml 14 22 <span type="species:ncbi:9606">Patients</span>
Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival
###end article-title 68
###begin article-title 69
Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium
###end article-title 69
###begin article-title 70
Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a Population-based Study
###end article-title 70
###begin article-title 71
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
###end article-title 71
###begin article-title 72
###xml 90 98 <span type="species:ncbi:9606">Patients</span>
p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
###end article-title 72
###begin article-title 73
LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer
###end article-title 73
###begin article-title 74
Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status
###end article-title 74
###begin article-title 75
###xml 133 139 <span type="species:ncbi:9606">humans</span>
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
###end article-title 75
###begin article-title 76
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome
###end article-title 76
###begin article-title 77
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
The single nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes
###end article-title 77
###begin article-title 78
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling
###end article-title 78
###begin article-title 79
The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies
###end article-title 79
###begin article-title 80
Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309
###end article-title 80
###begin article-title 81
MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia
###end article-title 81
###begin article-title 82
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
###end article-title 82
###begin article-title 83
Heterogeneity of breast cancer associations with five susceptibility Loci by clinical and pathological characteristics
###end article-title 83
###begin article-title 84
Reporting recommendations for tumor marker prognostic studies
###end article-title 84
###begin article-title 85
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
###end article-title 85
###begin article-title 86
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo
###end article-title 86
###begin article-title 87
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
###end article-title 87
###begin article-title 88
Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer
###end article-title 88
###begin article-title 89
###xml 161 169 <span type="species:ncbi:9606">Patients</span>
Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine/Proline Heterozygous Breast Cancer Patients
###end article-title 89
###begin article-title 90
###xml 59 67 <span type="species:ncbi:9606">Patients</span>
The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer
###end article-title 90
###begin article-title 91
###xml 18 23 <span type="species:ncbi:9606">human</span>
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
###end article-title 91
###begin article-title 92
###xml 25 30 <span type="species:ncbi:9606">human</span>
Assessing TP53 status in human tumours to evaluate clinical outcome
###end article-title 92
###begin article-title 93
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry
###end article-title 93
###begin article-title 94
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
###end article-title 94
###begin article-title 95
TP53 status and response to chemotherapy in breast cancer
###end article-title 95
###begin article-title 96
Kbiosciences, Cambridge, UK
###end article-title 96
###begin article-title 97
Taqman, Applied Biosystems
###end article-title 97
###begin article-title 98
Illumina
###end article-title 98
###begin article-title 99
###xml 66 71 <span type="species:ncbi:9606">Women</span>
Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation
###end article-title 99
###begin article-title 100
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer
###end article-title 100
###begin article-title 101
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients
###end article-title 101
###begin article-title 102
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients
###end article-title 102
###begin article-title 103
Genetic variants in epigenetic genes and breast cancer risk
###end article-title 103

